ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2022

Clinical Benefit of Switching from Low-Dose to High-Dose Empagliflozin in Patients with Type 2 Diabetes.

Takeshi Matsumura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.